Loading clinical trials...

Outpatient Recovery From Acute Kidney Injury Requiring Dialysis - 2 | Clinical Trials | Clareo Health

RECRUITINGNA

Outpatient Recovery From Acute Kidney Injury Requiring Dialysis - 2

NCT07106151•University of California, San Francisco

Summary

Providing additional information to patients with acute kidney injury who continue dialysis after hospital discharge and to the accepting kidney doctor (nephrologist) who manages their dialysis may be feasible and beneficial. This study will pilot measuring the patient's residual kidney function at the time of discharge and communicating that result to the accepting nephrologist and the patient, along with information on recommended recovery monitoring frequency and criteria for consideration of a twice-weekly hemodialysis schedule.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•AKI-D (not ESKD, as determined by the clinical inpatient nephrology team)
•Age ≥ 18 years
•Planned for continued dialysis outside the acute hospital setting (at outpatient dialysis unit/SNF/LTACH, not planned transfer to another short-stay acute care hospital).

Exclusion Criteria

•Pregnant
•Prisoner
•Unable to consent and no surrogate decision maker available
•Clinical team declines to allow approach for study

Locations (1)

University of California, San Francisco

San Francisco, California, United States

Key Dates

Start Date

February 23, 2026

Primary Completion Date

January 1, 2028

Completion Date

January 1, 2028

Last Updated

February 27, 2026

Enrollment

ESTIMATED participants

Conditions

AKIAKI - Acute Kidney InjuryDialysis Patients

Interventions

Transmission of additional AKI-D recovery information

BEHAVIORAL

No additional AKI-D recovery information

OTHER

Contacts

Ian E McCoy, MD, MS

CONTACT

415-353-2507 ian.mccoy@ucsf.edu

Frequency of Interrupting Sitting and Cognitive Function

NCT06700187

Sedentary BehaviorsBreaking Prolonged Sitting With Physical Activity

View study

RECRUITINGNA

Efficacy of Topical Coenzyme Q10 and Curcumin for Oral Leukoplakia Treatment

NCT07331935

Oral Leukoplakia

View study

RECRUITINGNA

Enhancing Generalization of Virtual Reality Exposure for Public Speaking Anxiety

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 27, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Outpatient Recovery From Acute Kidney Injury Requiring Dialysis - 2

Inclusion Criteria

Exclusion Criteria

Frequency of Interrupting Sitting and Cognitive Function

Efficacy of Topical Coenzyme Q10 and Curcumin for Oral Leukoplakia Treatment

Enhancing Generalization of Virtual Reality Exposure for Public Speaking Anxiety

Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia

Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy

Kawasaki MATCH Trial